Staff Members - Benha University
Secretion of glucagon- like peptide-1 (GLP-1) in type 2 diabetic patients: Study of its relation to glucose lowering effect of dipeptidyl peptidase IV (DPP-IV) inhibitors.
Nature and Science • 2015
Publication Information
Authors
Atef Ahmed Ebraheem1, Mohammed Shawky El-Sayed1, Roshdy Khalf Allah1, Khaled Mostafa Belal2,
Rizk Sayad Rizk Sarhan
Keywords
glucagon- like peptide-1, Type2 DM, dipeptidyl peptidase IV (DPP-IV) inhibitors,GLP-1 level, incretin
hormone, incretin based therapy.
Journal
Nature and Science
Publisher
Not Available
Volume
2015;13(6)
Issue
Not Available
Pages
75-87
publication.type
International
Paper Link
Open Link
Supplementary Materials
Not Available
Abstract
Th aims of this study are to investigate the glycemic efficy and predictive parameters of
DPP IV inhibitors therapy in Egyptian subjects with type 2 diabetes. (2) Investigate the level and the determinants
that affect the secretion of glucagone like peptide-1(GLP-1) in Type2 diabetic patients. Subjects and Methods:
This study was conducted on 70 type 2 diabetes patients【35 males & 35 females】 under known antidiabetic drugs,
Their ages range was (30-63y) and average mean (46.31±10.75 y), as well as 20 apparently healthy subject's
volunteers served as control 【12 males & 8 females】 with age range (28-50y) and SD (37.40±5.04 y). DPP-4
inhibitors were added to every patient after the start of the study. The patients were followed at monthly interval for
3 months after the beginning of DPP-4 inhibitors therapy. Results: GLP-1 levels were significantly decreased in
DM subjects compared to controls (261.33± 9.37 vs.75.48 ± 20.81pg/mL, p
DPP IV inhibitors therapy in Egyptian subjects with type 2 diabetes. (2) Investigate the level and the determinants
that affect the secretion of glucagone like peptide-1(GLP-1) in Type2 diabetic patients. Subjects and Methods:
This study was conducted on 70 type 2 diabetes patients【35 males & 35 females】 under known antidiabetic drugs,
Their ages range was (30-63y) and average mean (46.31±10.75 y), as well as 20 apparently healthy subject's
volunteers served as control 【12 males & 8 females】 with age range (28-50y) and SD (37.40±5.04 y). DPP-4
inhibitors were added to every patient after the start of the study. The patients were followed at monthly interval for
3 months after the beginning of DPP-4 inhibitors therapy. Results: GLP-1 levels were significantly decreased in
DM subjects compared to controls (261.33± 9.37 vs.75.48 ± 20.81pg/mL, p